Company

Ondine Biomedical Inc.

Headquarters: Vancouver, BC, Canada

CEO: Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA

LSE: OBI -4.88%

Detailed Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date June 30, 2023
Revenue TTM £470,750
EBITDA £-10,636,374
Gross Profit TTM £287,000
Profit Margin 44.98%
Operating Margin -1876.17%
Quarterly Revenue Growth 63.40%
Financial Reports & Statistics

Stocks & Indices

Ondine Biomedical Inc. has the following listings and related stock indices.


Stock: LSE: OBI wb_incandescent

Details

Headquarters:

1100 Melville Street

Vancouver, BC V6E 4A6

Canada

Phone: 604-669-0555